Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial
1
조회
0
다운로드
17
인용
0
참고문헌
키워드
초록
Background/Aims: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication. Methods: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)- based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases. Results: In total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences. Conclusions: TPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier NCT03317223).
Abstract
Background/Aims: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication. Methods: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)- based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases. Results: In total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences. Conclusions: TPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier NCT03317223).
참고문헌 (25)
- Jung Hye-Kyung, "Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020", Gut and Liver, 15(2), pp.168~195 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Uemura N, "Helicobacter pylori infection and the development of gastric cancer", N Engl J Med, 345, pp.784~789 (2001)
- Warren JR, "Unidentified curved bacilli on gastric epithelium in active chronic gastritis", Lancet, 1, pp.1273~1275 (1983)
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, "Schistosomes, liver flukes and Helicobacter pyloriLyon, 7-14 June 1994", IARC Monogr Eval Carcinog Risks Hum, 61, pp.1~241 (1994)
- Kim SG, "Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition", J Gastroenterol Hepatol, 29, pp.1371~1386 (2014)
- Malfertheiner P, "Management of Helicobacter pylori infection: the Maastricht V", Florence Consensus Report, pp.66, 6~30
- Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
- Scott D, "The life and death of Helicobacter pylori", Gut, 43(Suppl 1), pp.S56~S60 (1998)
- Xiong M, "Selective killing of Helicobacter pylori with pH-responsive helix-coil conformation transitionable antimicrobial polypeptides", Proc Natl Acad Sci U S A, 114, pp.12675~12680 (2017)
- Thung I, "Review article : the global emergence of Helicobacter pylori antibiotic resistance", Aliment Pharmacol Ther, 43, pp.514~533 (2016)
- Takahashi N, "Tegoprazan, a novel potassiumcompetitive acid blocker to control gastric acid secretion and motility", J Pharmacol Exp Ther, 364, pp.275~286 (2018)
- Inatomi N, "Potassiumcompetitive acid blockers : advanced therapeutic option for acid-related diseases", Pharmacol Ther, 168, pp.12~22 (2016)
- Lambrecht N, "Comparison of covalent with reversible inhibitor binding sites of the gastric H, K-ATPase by site-directed mutagenesis", J Biol Chem, 275, pp.4041~4048 (2000)
- Ghim JL, "Pharmacokinetics and pharmacodynamics of tegoprazan coadministered with amoxicillin and clarithromycin in healthy subjects", J Clin Pharmacol, 61, pp.913~922 (2021)
- Nishida T, "Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan", World J Gastroenterol, 20, pp.4362~4369 (2014)
- Murakami K, "Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication : a phase III, randomised, double-blind study", Gut, 65, pp.1439~1446 (2016)
- Han S, "Randomised clinical trial : safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan(CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects", Aliment Pharmacol Ther, 50, pp.751~759 (2019)
- Echizen H, "The first-in-class potassium-competitive acid blocker, vonoprazan fumarate : pharmacokinetic and pharmacodynamic considerations", Clin Pharmacokinet, 55, pp.409~418 (2016)
- Alarcón T, "Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints", Enferm Infecc Microbiol Clin, 35, pp.278~282 (2017)
- 김재연, "한국에서 지역에 따른 Helicobacter pylori 균주 내성", 대한소화기학회지, 57(4), pp.221~229 (2011), 대한소화기학회
- Tanabe H, "Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication", Ann Clin Microbiol Antimicrob, 17, pp.29~ (2018)
- Sanglutong L, "Ineffectiveness of 14-day vonoprazan-based dual therapy and vonoprazan-based triple therapy for Helicobacter pylori eradication in area of high clarithromycin resistance : a prospective randomized study", Gastroenterology, 158, pp.S‐571~ (2020)
- Dong SQ, "Review : a Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy : is superiority an illusion", Helicobacter, 22, pp.e12438~ (2017)
- Lee JH, "Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea : a prospective multicenter study", Helicobacter, 24, pp.e12592~ (2019)